#### Edgar Filing: ZIOPHARM ONCOLOGY INC - Form 4

Check this box	ΓES SECURITIES AND EXCHANGE Washington, D.C. 20549 Γ OF CHANGES IN BENEFICIAL OV SECURITIES	VNERSHIP OF States of the second states of the seco					
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 5 obligations may continue. See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							
(Print or Type Responses)							
1. Name and Address of Reporting Person FRAGIN GARY S	<ul> <li>2. Issuer Name and Ticker or Trading Symbol</li> <li>ZIOPHARM ONCOLOGY INC [ZIOP]</li> </ul>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) FRAGIN ASSET MANAGEMENT, 4925 ARLINGTON AVENUE	3. Date of Earliest Transaction (Month/Day/Year) 12/13/2006	X_ Director 10% Owner Officer (give title Other (specify below) below)					
(Street) RIVERDALE, NY 10471	4. If Amendment, Date Original Filed(Month/Day/Year)	<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> <li>Person</li> </ul>					
(City) (State) (Zip)	Table I - Non-Derivative Securities A	cquired, Disposed of, or Beneficially Owned					
(Instr. 3) any (Mo	Deemed 3. 4. Securities coution Date, if TransactionAcquired (A) or	5. Amount of Securities6. Ownership Form: Direct7. Nature of IndirectBeneficially Owned(D) or Indirect (I)Beneficial OwnershipFollowing Following Transaction(s) (Instr. 3 and 4)(Instr. 4)					
Common Stock, \$.001 par value		0 D					

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

### Edgar Filing: ZIOPHARM ONCOLOGY INC - Form 4

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	\$ 4.31					<u>(1)</u>	12/22/2014	Common Stock, \$.001 par value	15.020
Director Stock Option (right to buy)	\$ 5.01					04/26/2006	04/26/2016	Common Stock	15,000
Director Stock Option (right to buy)	\$ 6.49	12/13/2006		А	15,000	<u>(2)</u>	12/13/2016	Common Stock	15,000

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationships				
		Director	10% Owner	Officer	Other	
FRAGIN GARY S FRAGIN ASSET MANAC 4925 ARLINGTON AVEN RIVERDALE, NY 10471		Х				
Signatures						
/s/ Gary S. Fragin	01/24/2007					
<u>**</u> Signature of Reporting Person	Date					

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 7,515 shares vest on 12/22/05 and 7,514 shares vest on 12/22/06.
- (2) 5,000 shares vest on each of 12/13/07, 12/13/08 and 12/13/09.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.